An interventional study of LVAD Implant and Aspirin 100mg in Heart Failure, sponsored by Abbott Medical Devices. Completed at 51 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-27.
Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Heart Failure by Abbott — 6 open to participants now, 9 under way, none of them phase 3. Heart Failure · Abbott.
Among the 120 studies in Heart Failure by Abbott, this one is the 13th largest by enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2020, is one of 62 with no phase, and was the 105th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →6 of the 120 studies in Heart Failure by Abbott are open now, in 12 countries. Recruiting first, the newest first:
Abbott Medical Devices · Sites in Brazil, France, Germany and 6 more countries
Ages 18+
Abbott Medical Devices · Sites in United States
Ages 18+
Abbott Medical Devices · Sites in United States, Austria, Czechia and 5 more countries
Ages 18+
Abbott Medical Devices · Sites in Italy
Ages 18+
Abbott Medical Devices · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 4 · Phase 4 5
First in 2002; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 628 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 136 across the 72 interventional studies, 154 across the 45 observational. Of the 106 that completed or were terminated, 53 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Abbott Medical Devices, one of the names counted as Abbott. Under that name alone:
Abbott Medical Devices is the lead sponsor of 540 studies on the registry; 34 are open to participants now.
Of its 53 completed or terminated interventional studies of FDA-regulated products, 44 (83%) have results posted.
3 of the studies in Heart Failure by Abbott that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06436053Abbott Medical DevicesAcute Response to Left Bundle Branch Area Pacing With SyncAV | 2026-12-15 |
| NCT07877805Abbott Medical DevicesMerlin Expanded ECG NSR | 2027-01 |
| NCT07217392Abbott Medical DevicesLeft Bundle Branch Area Pacing (LBBAP) PMCF Study | 2027-04-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 120 studies in Heart Failure by Abbott, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, randomized, double-blinded, placebo-controlled clinical investigation of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo
This clinical investigation is a prospective, randomized, double-blinded, placebo-controlled study of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVAD Patients on the placebo arm will be given placebo medication
Device: LVAD Implant · Drug: Placebo oral tablet
LVAD Patients on the active arm will be given 100mg Aspirin
Device: LVAD Implant · Drug: Aspirin 100mg
Subjects will undergo Heartmate 3 LVAD implant prior to randomization
Subjects will be randomized to either Placebo or Aspirin post implant.
Subjects will be randomized to either Placebo or Aspirin post implant
Powered Primary Endpoint of Survival Free of Non-surgical Major Hemocompatibility Related Adverse Events
The primary end point was a composite of survival free of non-surgical major hemocompatibility related adverse events (specifically stroke, pump thrombosis, major non-surgical bleeding, and arterial peripheral thromboembolism) at 1-year post implant.
Time frame: 12 Months
Rates of Non-surgical Major Hemorrhagic Events
The rate of non-surgical hemorrhagic events were compared between the two arms of the study. Non-surgical Major Hemorrhagic events: Hemorrhagic event rate per patient year was calculated by dividing all non-surgical bleeding events and hemorrhagic stroke events by the cumulative years of study exposure.
Time frame: Through Study Completion with a Median Follow up of 14 Months
Rates of Bleeding Events
The bleeding rate was calculated by dividing the number of bleeding events by the cumulative duration of study exposure (years of support).
Time frame: Through Study Completion with a Median Follow up of 14 Months
Rates of Non-surgical Major Thrombotic Events
The rates of non-surgical major thrombotic events was compared between the two arms of the study. The thrombotic event rate per patient year was calculated by dividing the number of non-surgical ischemic strokes, pump thrombosis and arterial peripheral thromboembolic events by the cumulative years of study exposure
Time frame: Through Study Completion with a Median Follow up of 14 Months
Rates of Stroke
The stroke rate was calculated based on the number of strokes experienced by subjects, 14 days or more after device implant, and while on their treatment assignment, divided by the cumulative duration of study exposure (years of support).
Time frame: Through Study Completion with a Median Follow up of 14 Months
Survival Rates
The overall survival rate was analyzed using a Kaplan-Meier analysis and the treatment groups were compared using log-rank test. Survival was calculated starting at 14 days post implant.
Time frame: 24 Months
Risk of Non-Surgical Bleeding Events
Risk of non-surgical bleeding events was analyzed using a Kaplan-Meier analysis. The treatment groups were compared using a log-rank test.
Time frame: 24 Months
Rate of Rehospitalization
This study assessed changes in the rehospitalization as a result of removal of antiplatelet therapy from the antithrombotic regimen.
Time frame: Through Study Completion with a Median Follow up of 14 Months
Economic Cost Implications - Total Estimated Cost for Bleeding Events (CMS Cost Basis)
Cost of bleeding episodes was calculated based on a previously published economic model, adjusted for inflation using the US Bureau of Labor Statistics Medical Consumer Price Index. To ensure uniformity in care practices and relevance of the previously published model, only US subjects were included.
Time frame: 12 Months
Economic Cost Implications - Average Cost Per Bleeding Event
These values were derived by dividing the total estimated cost for bleeding events by the number of events to determine the average cost per bleeding event. Consequently, a measure of dispersion is not available for these outcomes.
Time frame: 12 Months
Economic Cost Implications - Average Cost Per Study Patient Over the First-year Post-implant
These values were derived by dividing the total estimated cost for bleeding events by the number of patients to obtain the average cost per study patient. Consequently, a measure of dispersion is not available for these outcomes.
Time frame: 12 Months
Economic Cost Implications - Cost of Bleeding Hospitalization for 1000 LVAD Implants Over the First-year Post-implant
Cost of bleeding episodes was calculated based on a previously published economic model, adjusted for inflation using the US Bureau of Labor Statistics Medical Consumer Price Index. To ensure uniformity in care practices and relevance of the previously published model, only US subjects were included.
Time frame: 12 Months
The study enrolled and randomized 628 subjects at 51 sites. Enrollment took place between July 2020 and September 2022, with the last subject follow up concluding in August 2023.
| Milestone | Placebo Arm | Aspirin Arm |
|---|---|---|
| Started | 314 | 314 |
| Completed | 296 | 293 |
| Not completed | 18 | 21 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Withdrawal by subject | 9 | 7 |
| Withdrew: Transitioned to open label | 8 | 12 |
| Milestone | Placebo Arm | Aspirin Arm |
|---|---|---|
| Started | 296 | 293 |
| Completed | 271 | 273 |
| Not completed | 25 | 20 |
| Withdrew: Withdrawn without primary end point event | 25 | 20 |
The primary end point was a composite of survival free of non-surgical major hemocompatibility related adverse events (specifically stroke, pump thrombosis, major non-surgical bleeding, and arterial peripheral thromboembolism) at 1-year post implant.
| Participants | Placebo Arm (Principal Analysis Population) | Aspirin Arm (Principal Analysis Population) |
|---|---|---|
| Powered Primary Endpoint of Survival Free of Non-surgical Major Hemocompatibility Related Adverse Events | 201 | 186 |
The rate of non-surgical hemorrhagic events were compared between the two arms of the study. Non-surgical Major Hemorrhagic events: Hemorrhagic event rate per patient year was calculated by dividing all non-surgical bleeding events and hemorrhagic stroke events by the cumulative years of study exposure.
| Event Per 100 Patient-Year | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| All Non-surgical Major Hemorrhagic events | 26.2 | 40.7 |
| Bleeding | 25.93 | 39.53 |
| Hemorrhagic Stroke | 0.27 | 0.85 |
| Ischemic Stroke with Hemorrhagic Conversion | 0.00 | 0.28 |
The bleeding rate was calculated by dividing the number of bleeding events by the cumulative duration of study exposure (years of support).
| Event Per 100 Patient-Year | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| All Bleeding Events | 25.92 | 39.53 |
| Moderate Bleeding | 8.46 | 13.65 |
| Severe Bleeding | 17.47 | 25.88 |
| GI Bleeding | 13.10 | 21.61 |
| Fatal Bleeding | 0.55 | 0.85 |
The rates of non-surgical major thrombotic events was compared between the two arms of the study. The thrombotic event rate per patient year was calculated by dividing the number of non-surgical ischemic strokes, pump thrombosis and arterial peripheral thromboembolic events by the cumulative years of study exposure
| Event Per 100 Patient-Year | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| All Major Thrombotic events | 1.64 | 2.84 |
| Ischemic Stroke without Hemorrhagic Conversion | 1.64 | 2.56 |
| Device Thrombosis | 0.00 | 0.00 |
| Arterial Peripheral Thromboembolism | 0.00 | 0.00 |
The stroke rate was calculated based on the number of strokes experienced by subjects, 14 days or more after device implant, and while on their treatment assignment, divided by the cumulative duration of study exposure (years of support).
| Event Per 100 Patient-Year | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| All Stroke | 1.91 | 3.70 |
| Debilitating Stroke (MRS>3) | 0.82 | 0.57 |
| Non-Debilitating Stroke (MRS<=3) | 1.09 | 3.13 |
The overall survival rate was analyzed using a Kaplan-Meier analysis and the treatment groups were compared using log-rank test. Survival was calculated starting at 14 days post implant.
| Percentage of Participants | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| Survival Rates | 93 | 89.7 |
Risk of non-surgical bleeding events was analyzed using a Kaplan-Meier analysis. The treatment groups were compared using a log-rank test.
| Percentage of Participants | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| Risk of Non-Surgical Bleeding Events | 30.0 | 42.4 |
This study assessed changes in the rehospitalization as a result of removal of antiplatelet therapy from the antithrombotic regimen.
| Event Per 100 Patient-Year | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| Hemocompatibility Related | 0.15 | 0.28 |
| Major Infection | 0.34 | 0.36 |
| Hypertension | 0.03 | 0.02 |
| Cardiovascular Related | 0.33 | 0.33 |
| Non-cardiovascular organ dysfunction | 0.06 | 0.05 |
| Neurologic dysfunction (excluding stroke, TIA) | 0.01 | 0.02 |
| Other | 0.41 | 0.42 |
Cost of bleeding episodes was calculated based on a previously published economic model, adjusted for inflation using the US Bureau of Labor Statistics Medical Consumer Price Index. To ensure uniformity in care practices and relevance of the previously published model, only US subjects were included.
| USD | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| Economic Cost Implications - Total Estimated Cost for Bleeding Events (CMS Cost Basis) | 546,947 | 927,040 |
These values were derived by dividing the total estimated cost for bleeding events by the number of events to determine the average cost per bleeding event. Consequently, a measure of dispersion is not available for these outcomes.
| USD | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| Economic Cost Implications - Average Cost Per Bleeding Event | 13,674 | 13,836 |
These values were derived by dividing the total estimated cost for bleeding events by the number of patients to obtain the average cost per study patient. Consequently, a measure of dispersion is not available for these outcomes.
| USD | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| Economic Cost Implications - Average Cost Per Study Patient Over the First-year Post-implant | 2,214 | 3,799 |
Cost of bleeding episodes was calculated based on a previously published economic model, adjusted for inflation using the US Bureau of Labor Statistics Medical Consumer Price Index. To ensure uniformity in care practices and relevance of the previously published model, only US subjects were included.
| USD/1000 implants/1 year | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| Economic Cost Implications - Cost of Bleeding Hospitalization for 1000 LVAD Implants Over the First-year Post-implant | 2,214,362 | 3,799,344 |
Collected over All adverse events occurring through study completion (median follow up of 14 months) were collected.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Arm (Modified Intent-to-treat Population) | 21/296 (7.1%) | 208/296 (70.3%) | 200/296 (67.6%) |
| Aspirin Arm (Modified Intent-to-treat Population) | 22/293 (7.5%) | 223/293 (76.1%) | 181/293 (61.8%) |
| Event | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| Major InfectionInfections and infestations | 99/296 | 116/293 |
| BleedingBlood and lymphatic system disorders | 68/296 | 100/293 |
| Cardiac ArrhythmiaCardiac disorders | 44/296 | 41/293 |
| Cardiac DisordersCardiac disorders | 33/296 | 35/293 |
| Metabolism And Nutrition DisordersMetabolism and nutrition disorders | 32/296 | 33/293 |
| General Disorders And Administration Site ConditionsGastrointestinal disorders | 31/296 | 24/293 |
| Nervous System DisordersNervous system disorders | 22/296 | 26/293 |
| Neurologic DysfunctionNervous system disorders | 25/296 | 21/293 |
| Respiratory, Thoracic And Mediastinal DisordersRespiratory, thoracic and mediastinal disorders | 25/296 | 24/293 |
| Gastrointestinal DisordersGastrointestinal disorders | 24/296 | 13/293 |
| Event | Placebo Arm (Modified Intent-to-treat Population) | Aspirin Arm (Modified Intent-to-treat Population) |
|---|---|---|
| Major InfectionInfections and infestations | 94/296 | 92/293 |
| Metabolism And Nutrition DisordersMetabolism and nutrition disorders | 43/296 | 33/293 |
| Cardiac DisordersCardiac disorders | 42/296 | 23/293 |
| Nervous System DisordersNervous system disorders | 40/296 | 26/293 |
| Vascular DisordersVascular disorders | 36/296 | 39/293 |
| General Disorders And Administration Site ConditionsGeneral disorders | 34/296 | 21/293 |
| InvestigationsInvestigations | 25/296 | 29/293 |
| Respiratory, Thoracic And Mediastinal DisordersRespiratory, thoracic and mediastinal disorders | 25/296 | 27/293 |
| Injury, Poisoning And Procedural ComplicationsInjury, poisoning and procedural complications | 20/296 | 24/293 |
| Gastrointestinal DisordersGastrointestinal disorders | 21/296 | 18/293 |
The Modified Intention to Treat Population (mITT) included all randomized subjects with the following exception: 1. Subjects who experienced a surgical adverse event, defined as ≤14 days post-implant, requiring investigator mandated antiplatelet therapy; 2. Subjects who expired, are transplanted, or withdrawn within 14 days of implant.
| Age, Continuous(years) | Placebo Arm | Aspirin Arm | Total |
|---|---|---|---|
| Mean | 57.6 ± 12.8 | 56.5 ± 14.4 | 57.1 ± 13.6 |
| Sex: Female, Male(Participants) | Placebo Arm | Aspirin Arm | Total |
|---|---|---|---|
| Female | 72 | 61 | 133 |
| Male | 224 | 232 | 456 |
| Race (NIH/OMB)(Participants) | Placebo Arm | Aspirin Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 13 | 9 | 22 |
| Native Hawaiian or Other Pacific Islander | 2 | 3 | 5 |
| Black or African American | 93 | 84 | 177 |
| White | 179 | 181 | 360 |
| More than one race | 3 | 3 | 6 |
| Unknown or Not Reported | 6 | 13 | 19 |
| Heart Failure Etiology(Participants) | Placebo Arm | Aspirin Arm | Total |
|---|---|---|---|
| Ischemic Cardiomyopathy | 106 | 101 | 207 |
| Idiopathic Cardiomyopathy | 68 | 63 | 131 |
| Dilated Cardiomyopathy | 86 | 81 | 167 |
| Other | 36 | 48 | 84 |
| Intended Use(Participants) | Placebo Arm | Aspirin Arm | Total |
|---|---|---|---|
| Bridge to Transplantation | 56 | 58 | 114 |
| Bridge to Candidacy for Transplantation | 46 | 50 | 96 |
| Destination Therapy | 180 | 174 | 354 |
| Bridge to Recovery | 14 | 11 | 25 |
| INTERMACS Profile(Participants) | Placebo Arm | Aspirin Arm | Total |
|---|---|---|---|
| 1 | 12 | 18 | 30 |
| 2 | 76 | 75 | 151 |
| 3 | 133 | 133 | 266 |
| 4 | 66 | 54 | 120 |
| 5 | 6 | 8 | 14 |
| 6 | 3 | 5 | 8 |
| 7 | 0 | 0 | 0 |
| New York Heart Association (NYHA) Class(Participants) | Placebo Arm | Aspirin Arm | Total |
|---|---|---|---|
| Class II | 3 | 2 | 5 |
| Class IIIA | 27 | 29 | 56 |
| Class IIIB | 40 | 38 | 78 |
| Class IV | 226 | 224 | 450 |
| Region of Enrollment(Participants) | Placebo Arm | Aspirin Arm | Total |
|---|---|---|---|
| North America | 251 | 248 | 499 |
| Other | 45 | 45 | 90 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — To be determined
Ran from Jul 2020 to primary completion in Aug 2023, 36 months.
Results were first posted in Mar 2025, 1 year 7 months after primary completion.
Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 62. This study's 36 months is close to that.
Counting every sponsor, half of 1,354 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin